TY - JOUR
T1 - Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies
AU - Perani, Daniela
AU - Iaccarino, Leonardo
AU - Jacobs, Andreas H.
AU - Lammertsma, Adriaan A.
AU - Nordberg, Agneta
AU - Windhorst, Albert D.
AU - Gerhard, Alexander
AU - Winkeler, Alexandra
AU - Gee, Anthony
AU - Kuhnast, Bertrand
AU - Halldin, Christer
AU - Brooks, David
AU - Rodriguez-Vieitez, Elena
AU - Turkheimer, Federico E.
AU - López-Picón, Francisco
AU - Knudsen, Gitte M.
AU - Vercouillie, Johnny
AU - Rinne, Juha O.
AU - Herholz, Karl
AU - Van Laere, Koen
AU - Santiago-Ribeiro, Marie Joao
AU - Herth, Matthias M.
AU - Carroll, Michael A.
AU - Bottlaender, Michel
AU - Hansson, Oskar
AU - Edison, Paul
AU - Hinz, Rainer
AU - Boellaard, Ronald
AU - Moresco, Rosa Maria
AU - Pappata, Sabina
AU - IMBI Brain Imaging Working Group
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Introduction: A rapid transition from a clinical-based classification to a pathology-based classification of neurodegenerative conditions, largely promoted by the increasing availability of imaging biomarkers, is emerging. The Framework for Innovative Multi-tracer molecular Brain Imaging, funded by the EU Joint Program - Neurodegenerative Disease Research 2016 “Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration,” aimed at providing a roadmap for the applications of established and new molecular imaging techniques in dementia. Methods: We consider current and future implications of adopting a pathology-based framework for the use and development of positron emission tomography techniques. Results: This approach will enhance efforts to understand the multifactorial etiology of Alzheimer's disease and other dementias. Discussion: The availability of pathology biomarkers will soon transform clinical and research practice. Crucially, a comprehensive understanding of strengths and caveats of these techniques will promote an informed use to take full advantage of these tools.
AB - Introduction: A rapid transition from a clinical-based classification to a pathology-based classification of neurodegenerative conditions, largely promoted by the increasing availability of imaging biomarkers, is emerging. The Framework for Innovative Multi-tracer molecular Brain Imaging, funded by the EU Joint Program - Neurodegenerative Disease Research 2016 “Working Groups for Harmonisation and Alignment in Brain Imaging Methods for Neurodegeneration,” aimed at providing a roadmap for the applications of established and new molecular imaging techniques in dementia. Methods: We consider current and future implications of adopting a pathology-based framework for the use and development of positron emission tomography techniques. Results: This approach will enhance efforts to understand the multifactorial etiology of Alzheimer's disease and other dementias. Discussion: The availability of pathology biomarkers will soon transform clinical and research practice. Crucially, a comprehensive understanding of strengths and caveats of these techniques will promote an informed use to take full advantage of these tools.
KW - Amyloid
KW - Neuroinflammation
KW - PET molecular imaging
KW - Protheinopathies
KW - Radiotracers
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=85064440586&partnerID=8YFLogxK
U2 - 10.1016/j.dadm.2019.02.004
DO - 10.1016/j.dadm.2019.02.004
M3 - Journal article
C2 - 31080871
AN - SCOPUS:85064440586
SN - 2352-8729
VL - 11
SP - 327
EP - 332
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
ER -